The invention discloses a nasal composition of improved stability their use and process for production. The nasal composition consists of: xylometazoline hydrochloride (1) 0.01 0.1% w/w ipratropium bromide (2) 0.01 0.1% w/w and pharmaceutical excipients required to form final dosage forms selected from the group consisting of: nasal drops liquid nasal sprays or nasal washes. Said nasal composition comprises the content of purified sea water as functional stability improving excipient in amounts of 5 25% w/w. A nasal composition has osmolality within the range 270 820 mOsm/kg the pH value within the range 3 7 preferably within the range 3 4.2 or 5.8 7.0 and most preferably within the range 3.2 4.2 where shows improved stability.
